Population pharmacokinetic-pharmacogenetic model of tacrolimus in the early period after kidney transplantation

Basic and Clinical Pharmacology and Toxicology

Volumn 114, Issue 5, 2014, Pages 400-406

  Han, Nayoung ^a   Ha, Soojung ^a   Yun, Hwi Yeol ^b   Kim, Myeong Gyu ^a   Min, Sang Il ^c   Ha, Jongwon ^c   Lee, Jangik Ike ^d   Oh, Jung Mi ^a   Kim, In Wha ^a  

^a Seoul National University   (South Korea)

^b Chungnam National University   (South Korea)

^c Seoul National University College of Medicine   (South Korea)

^d Yonsei University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 3A5; METHYLPREDNISOLONE; MULTIDRUG RESISTANCE PROTEIN 1; MYCOPHENOLIC ACID; PREDNISOLONE; TACROLIMUS; ABCB1 PROTEIN, HUMAN; CYP3A5 PROTEIN, HUMAN; CYTOCHROME P450 3A; IMMUNOSUPPRESSIVE AGENT; MULTIDRUG RESISTANCE PROTEIN;

ADULT; ARTICLE; BAYES THEOREM; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE REDUCTION; DRUG ELIMINATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GENE FREQUENCY; GENOTYPE; GRAFT RECIPIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; POPULATION MODEL; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; BIOLOGICAL MODEL; GENETICS; MIDDLE AGED; NONLINEAR SYSTEM; PHARMACOGENETICS; RETROSPECTIVE STUDY; TIME; TISSUE DISTRIBUTION;

ADULT; BAYES THEOREM; CYTOCHROME P-450 CYP3A; FEMALE; GENOTYPE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; NONLINEAR DYNAMICS; P-GLYCOPROTEINS; PHARMACOGENETICS; POSTOPERATIVE PERIOD; RETROSPECTIVE STUDIES; TACROLIMUS; TIME FACTORS; TISSUE DISTRIBUTION;

EID: 84897962292     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/bcpt.12176     Document Type: Article

References (35)

1. Plosker GL, Foster RH. Tacrolimus: a further update of its pharmacology and therapeutic use in the management of organ transplantation. Drugs 2000;59:323-89.
2. Kidokoro K, Satoh M, Nagasu H, Sakuta T, Kuwabara A, Yorimitsu D et al. Tacrolimus induces glomerular injury via endothelial dysfunction caused by reactive oxygen species and inflammatory change. Kidney Blood Press Res 2012;35:549-57.
3. Staatz C, Taylor P, Tett S. Low tacrolimus concentrations and increased risk of early acute rejection in adult renal transplantation. Nephrol Dial Transplant 2001;16:1905-9.
4. Ceschi A, Rauber-Luthy C, Kupferschmidt H, Banner NR, Ansari M, Krahenbuhl S et al. Acute calcineurin inhibitor overdose: analysis of cases reported to a national poison center between 1995 and 2011. Am J Transplant 2013;13:786-95.
5. Ogasawara K, Chitnis SD, Gohh RY, Christians U, Akhlaghi F. Multidrug resistance-associated protein 2 (MRP2/ABCC2) haplotypes significantly affect the pharmacokinetics of tacrolimus in kidney transplant recipients. Clin Pharmacokinet 2013;52:751-62.
6. Zuo XC, Ng CM, Barrett JS, Luo AJ, Zhang BK, Deng CH et al. Effects of CYP3A4 and CYP3A5 polymorphisms on tacrolimus pharmacokinetics in Chinese adult renal transplant recipients: a population pharmacokinetic analysis. Pharmacogenet Genomics 2013;23:251-61.
7. Kim IW, Noh H, Ji E, Han N, Hong SH, Ha J et al. Identification of factors affecting tacrolimus level and 5-year clinical outcome in kidney transplant patients. Basic Clin Pharmacol Toxicol 2012;111:217-23.
8. Kuypers DR, de Jonge H, Naesens M, Lerut E, Verbeke K, Vanrenterghem Y. CYP3A5 and CYP3A4 but not MDR1 single-nucleotide polymorphisms determine long-term tacrolimus disposition and drug-related nephrotoxicity in renal recipients. Clin Pharmacol Ther 2007;82:711-25.
9. Iwasaki K. Metabolism of tacrolimus (FK506) and recent topics in clinical pharmacokinetics. Drug Metab Pharmacokinet 2007;22:328-35.
10. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001;27:383-91.
11. Kim IW, Moon YJ, Ji E, Kim KI, Han N, Kim SJ et al. Clinical and genetic factors affecting tacrolimus trough levels and drug-related outcomes in Korean kidney transplant recipients. Eur J Clin Pharmacol 2012;68:657-69.
12. Anglicheau D, Verstuyft C, Laurent-Puig P, Becquemont L, Schlageter MH, Cassinat B et al. Association of the multidrug resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients. J Am Soc Nephrol 2003;14:1889-96.
13. Asano T, Nishimoto K, Hayakawa M. Increased tacrolimus trough levels in association with severe diarrhea, a case report. Transplant Proc 2004;36:2096-7.
14. Macphee IA, Fredericks S, Tai T, Syrris P, Carter ND, Johnston A et al. Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome p4503A5 and P-glycoprotein correlate with dose requirement. Transplantation 2002;74:1486-9.
15. Pollock-Barziv SM, Finkelstein Y, Manlhiot C, Dipchand AI, Hebert D, Ng VL et al. Variability in tacrolimus blood levels increases the risk of late rejection and graft loss after solid organ transplantation in older children. Pediatr Transplant 2010;14:968-75.
16. Basadonna GP, Matas AJ, Gillingham KJ, Payne WD, Dunn DL, Sutherland DE et al. Early versus late acute renal allograft rejection: impact on chronic rejection. Transplantation 1993;55:993-5.
17. O'Seaghdha CM, McQuillan R, Moran AM, Lavin P, Dorman A, O'Kelly P et al. Higher tacrolimus trough levels on days 2-5 post-renal transplant are associated with reduced rates of acute rejection. Clin Transplant 2009;23:462-8.
18. Antignac M, Fernandez C, Barrou B, Roca M, Favrat JL, Urien S et al. Prediction tacrolimus blood levels based on the Bayesian method in adult kidney transplant patients. Eur J Drug Metab Pharmacokinet 2011;36:25-33.
19. Benkali K, Premaud A, Picard N, Rerolle JP, Toupance O, Hoizey G et al. Tacrolimus population pharmacokinetic-pharmacogenetic analysis and Bayesian estimation in renal transplant recipients. Clin Pharmacokinet 2009;48:805-16.
20. Staatz CE, Willis C, Taylor PJ, Tett SE. Population pharmacokinetics of tacrolimus in adult kidney transplant recipients. Clin Pharmacol Ther 2002;72:660-9.
21. Han N, Yun HY, Hong JY, Kim IW, Ji E, Hong SH et al. Prediction of the tacrolimus population pharmacokinetic parameters according to CYP3A5 genotype and clinical factors using NONMEM in adult kidney transplant recipients. Eur J Clin Pharmacol 2013;69:53-63.
22. The World Medical Association Declaration of Helsinki - Ethical Principles for Medical Research Involving Human Subjects. 64th WMA General Assembly, Fortaleza, Brazil, October 2013. http://www.wma.net/en/30publications/10policies/b3/ (last accessed on 27 November 2013).
23. Hooker AC, Staatz CE, Karlsson MO. Conditional weighted residuals (CWRES): a model diagnostic for the FOCE method. Pharm Res 2007;24:2187-97.
24. Bergstrand M, Hooker AC, Wallin JE, Karlsson MO. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J 2011;13:143-51.
25. Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 1981;9:503-12.
26. Oteo I, Lukas JC, Leal N, Suarez E, Valdivieso A, Gastaca M et al. Tacrolimus pharmacokinetics in the early post-liver transplantation period and clinical applicability via Bayesian prediction. Eur J Clin Pharmacol 2013;69:65-74.
27. Proost JH. Adaptive control of drug dosage regimens using maximum a posteriori probability Bayesian fitting. Int J Clin Pharmacol Ther 1995;33:531-6.
28. Antignac M, Barrou B, Farinotti R, Lechat P, Urien S. Population pharmacokinetics and bioavailability of tacrolimus in kidney transplant patients. Br J Clin Pharmacol 2007;64:750-7.
29. Fukatsu S, Yano I, Igarashi T, Hashida T, Takayanagi K, Saito H et al. Population pharmacokinetics of tacrolimus in adult recipients receiving living-donor liver transplantation. Eur J Clin Pharmacol 2001;57:479-84.
30. Jusko WJ. Analysis of tacrolimus (FK 506) in relation to therapeutic drug monitoring. Ther Drug Monit 1995;17:596-601.
31. Tuteja S, Alloway RR, Johnson JA, Gaber AO. The effect of gut metabolism on tacrolimus bioavailability in renal transplant recipients. Transplantation 2001;71:1303-7.
32. Passey C, Birnbaum AK, Brundage RC, Oetting WS, Israni AK, Jacobson PA. Dosing equation for tacrolimus using genetic variants and clinical factors. Br J Clin Pharmacol 2011;72:948-57.
33. Thervet E, Loriot MA, Barbier S, Buchler M, Ficheux M, Choukroun G et al. Optimization of initial tacrolimus dose using pharmacogenetic testing. Clin Pharmacol Ther 2010;87:721-6.
34. Zhao W, Elie V, Roussey G, Brochard K, Niaudet P, Leroy V et al. Population pharmacokinetics and pharmacogenetics of tacrolimus in de novo pediatric kidney transplant recipients. Clin Pharmacol Ther 2009;86:609-18.
35. Zhang GM, Li L, Chen WQ, Bi SS, Liu X, Zhang XL et al. Population pharmacokinetics of tacrolimus in Chinese renal transplant patients. Yao Xue Xue Bao 2008;43:695-701.